Related Experiment Video
Updated: Jun 24, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
A glucuronidation pathway of capecitabine occurs in rats but not in mice and humans
F Desmoulin1, C Claparols, D Bon
1Groupe de RMN Biomédicale, LSPCMIB UMR - CNRS 5068, Bât. 2R1, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cedex 9, France. desmoulin@chimie.ups-tlse.fr
Abstract:
Glucuronidation of 5'-DFCR, a metabolite of capecitabine, was confirmed in experimental models from rats whereas 5'-DFCR glucuronide was detected neither in bile or liver from mice nor in liver microsomes from human. Metabolic interactions at the level of the glucuronidation pathway between CAP and other drugs are unlikely in patients.
Related Concept Videos
Phase II Reactions: Glucuronidation
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Metabolism: Phase II Reactions